



The Burden Attributable to Mental and Substance Use Disorders as Risk Factors for Suicide: Findings from the Global Burden of Disease Study 2010

Alize J. Ferrari^{1,2*}, Rosana E. Norman^{1,3}, Greg Freedman⁴, Amanda J. Baxter^{1,2}, Jane E. Pirkis⁵, Meredith G. Harris^{1,2}, Andrew Page⁶, Emily Carnahan⁴, Louisa Degenhardt^{5,7}, Theo Vos^{1,4}, Harvey A. Whiteford^{1,2}

1 University of Queensland, School of Population Health, Herston, Queensland, Australia, **2** Queensland Centre for Mental Health Research, Wacol, Queensland, Australia, **3** Queensland Children's Medical Research Institute, University of Queensland, Herston, Queensland, Australia, **4** Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States of America, **5** Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia, **6** School of Science and Health, University of Western Sydney, Campbelltown, New South Wales, Australia, **7** National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia

Abstract

Background: The Global Burden of Disease Study 2010 (GBD 2010) identified mental and substance use disorders as the 5th leading contributor of burden in 2010, measured by disability adjusted life years (DALYs). This estimate was incomplete as it excluded burden resulting from the increased risk of suicide captured elsewhere in GBD 2010's mutually exclusive list of diseases and injuries. Here, we estimate suicide DALYs attributable to mental and substance use disorders.

Methods: Relative-risk estimates of suicide due to mental and substance use disorders and the global prevalence of each disorder were used to estimate population attributable fractions. These were adjusted for global differences in the proportion of suicide due to mental and substance use disorders compared to other causes then multiplied by suicide DALYs reported in GBD 2010 to estimate attributable DALYs (with 95% uncertainty).

Results: Mental and substance use disorders were responsible for 22.5 million (14.8–29.8 million) of the 36.2 million (26.5–44.3 million) DALYs allocated to suicide in 2010. Depression was responsible for the largest proportion of suicide DALYs (46.1% (28.0%–60.8%)) and anorexia nervosa the lowest (0.2% (0.02%–0.5%)). DALYs occurred throughout the lifespan, with the largest proportion found in Eastern Europe and Asia, and males aged 20–30 years. The inclusion of attributable suicide DALYs would have increased the overall burden of mental and substance use disorders (assigned to them in GBD 2010 as a direct cause) from 7.4% (6.2%–8.6%) to 8.3% (7.1%–9.6%) of global DALYs, and would have changed the global ranking from 5th to 3rd leading cause of burden.

Conclusions: Capturing the suicide burden attributable to mental and substance use disorders allows for more accurate estimates of burden. More consideration needs to be given to interventions targeted to populations with, or at risk for, mental and substance use disorders as an effective strategy for suicide prevention.

Citation: Ferrari AJ, Norman RE, Freedman G, Baxter AJ, Pirkis JE, et al. (2014) The Burden Attributable to Mental and Substance Use Disorders as Risk Factors for Suicide: Findings from the Global Burden of Disease Study 2010. PLoS ONE 9(4): e91936. doi:10.1371/journal.pone.0091936

Editor: Bernhard T. Baune, University of Adelaide, Australia

Received: October 27, 2013; **Accepted:** February 16, 2014; **Published:** April 2, 2014

Copyright: © 2014 Ferrari et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: AJF, AJB, MGH and HAW are associated with the Queensland Centre for Mental Health Research which acquires funding from the Queensland Department of Health. REN, GF, EC and TV received funding for the Global Burden of Disease project from the Bill and Melinda Gates Foundation. LD is supported by an Australian National Health and Medical Research Council (NHMRC) Principal Research Fellowship. The National Drug and Alcohol Research Centre at the University of NSW is supported by funding from the Australian Government under the Substance Misuse Prevention and Service Improvements Grants Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: alize_ferrari@qcmhr.uq.edu.au

Introduction

There has been growing recognition of the importance of mental and substance use disorders as contributors to health loss in all countries. The Global Burden of Disease Study 2010 (GBD 2010) is the largest and most recent effort to quantify this by systematically integrating years of life lost (YLLs) and years of life with disability (YLDs) into disability adjusted life years (DALYs) for diseases, injuries and risk factors [1–7].

GBD 2010 presented age-, sex-, year-, country-, and region-specific DALYs for 291 diseases and injuries as well as for 67 risk factors [1–7]; using improved methodology compared to previous GBD studies [8,9]. Mental and substance use disorders explained 7.4% (95% uncertainty interval: 6.2–8.6%) of total DALYs in 2010, confirming them as the leading disease category of YLDs, and the 5th leading category of DALYs globally [10–12]. This estimate reflects 'direct burden' where mental and substance use disorders are the direct cause of health loss, but excludes the excess

(attributable) burden resulting from the increased risk of mortality and disability due to subsequent health outcomes captured elsewhere in the mutually exclusive disease and injury categories in GBD 2010. Jointly considering the direct and the attributable burden of mental and substance use disorders provides an estimation of the putative causal relationship between the disorders and other health outcomes. This is of clinical and policy relevance as it clearly delineates the disability and mortality that potentially can be modified by interventions to prevent and treat mental and substance use disorders.

Here, we expand on the published GBD 2010 findings by estimating the additional burden attributable to mental and substance use disorders as risk factors for suicide. Suicide, defined as deaths caused by intentional, self-inflicted poisoning or injury [13], was the 13th leading cause of YLLs worldwide in 2010 [1,6]. Nearly 1 million people complete suicide every year with over 50% aged between 15 and 44 years [14,15]. Over 80% of suicides occur in low to middle income countries and close to 50% occur in India and China alone [15,16]. Suicide from firearms, car exhaust and poisoning are more common in high income countries and suicide from pesticide poisoning, hanging and self-immolation are more common in low to middle income countries [17]. It is important to consider these differences in the global epidemiology of suicide while quantifying the suicide burden attributable to mental and substance use disorders.

The link between mental and substance use disorders and suicide is well documented [14–20] and authors such as Prince and colleagues argued [14] that failure to include suicide as part of mental and substance use disorder estimates in the previous GBD studies [8,9] led to an underestimate of the extent of the burden. A literature review and meta-analysis by Harris and Barraclough showed that of the 249 studies and 44 mental disorders assessed, 36 disorders were associated with an increased risk of suicide [19]. Li and collaborators also found that the risk of suicide was 7.5 (6.2–9.0) times higher in males and 11.7 (9.7–14.1) times higher in females with a mental or substance use disorder compared to males and females with no disorder. Depression and bipolar disorder accounted for the highest risk [20]. Even when other risk factors such as adverse marital effects, employment and socio-economic status were considered, mental and substance use disorders remain strongly associated with suicide [20,21].

Quantifying the suicide burden attributable to mental and substance use disorders also corrects for the low burden from premature mortality (YLLs) directly attributed to mental and substance use disorders in GBD 2010. Although mental and substance use disorders were identified as a leading cause of global burden, YLDs contributed to 95% of DALYs [5,10]. In spite of evidence of excess mortality attributable to many mental and substance use disorders, only substance use disorders, anorexia nervosa, and schizophrenia are recognized as underlying causes of death in the International Classification of Diseases (ICD-10) cause of death guidelines [13] used in GBD 2010. Even for those disorders, few deaths were captured in the vital registrations used in the estimation of YLLs, as this typically involves the cumbersome task of disentangling the effect of multiple mental, substance and physical disorders to identify primary cause of death.

Investigating mental and substance use disorders as risk factors for fatal outcomes like suicide allows us to circumvent this problem by making use of GBD 2010's comparative risk analysis (CRA) methodology [7]. Rather than rely on certification and coding practices in mortality registration systems, this method allows quantification of the difference in population health in a counterfactual with a theoretical minimum level of exposure [7].

We make use of this method here to calculate the suicide burden attributable to mental and substance use disorders, and examine variations by region, country, age, year and disorder.

Methods

The suicide burden attributable to mental and substance use disorders was estimated by comparing the current health status with a theoretical-minimum-risk exposure defined as the counterfactual status of the absence of mental and substance use disorders. Population attributable fractions (PAFs) were determined from the prevalence of exposure to each disorder and the relative-risk (RR) of suicide [7]. For each disorder this involved:

1. Reviewing the strength of the evidence for a causal relationship between the disorder and suicide.
2. Expanding on existing systematic reviews of the literature quantifying the effect size for the disorder as a risk factor for suicide. The preferred metric was population-representative RR estimates.
3. Pooling all RR estimates using meta-analysis.
4. Combining the pooled RR estimate with GBD 2010 prevalence estimates to generate PAFs by age, sex, country, and year.
5. Adjusting PAFs for global differences in suicide attributable to mental and substance use disorders versus differences attributable to other causes.
6. Multiplying PAFs by suicide YLLs reported in GBD 2010 to estimate attributable burden.

Case definition

GBD methods suggest that for each risk factor-outcome pairing, there should be (1) sufficient data to enable estimation of relative effect sizes as well as (2) sufficient evidence for a causal effect [7]. A literature review by Baxter and collaborators [22] as well as other studies summarised in the previous section [14–20] investigating mental and substance use disorders as risk factors for other health outcomes found sufficient evidence to meet these two conditions for suicide.

Mental and substance use disorders investigated were those included in GBD 2010 for which there was evidence of an increased risk of suicide [10,19,20]. These were major depressive disorder (MDD), bipolar disorder, schizophrenia, anxiety disorder, anorexia nervosa, alcohol dependence, amphetamine dependence, cocaine dependence and opioid dependence. All disorders were defined using the Diagnostic and Statistical Manual of Mental Disorders (DSM) [23] or ICD diagnostic criteria [13]. Suicide was defined as cases meeting ICD-10 cause of death codes for intentional self-inflicted poisoning or injury (X60–X84) [13]. In some countries a large proportion of injury-related deaths are coded as ‘underdetermined intent’ for cultural, religious or medico-legal reasons. GBD 2010 developed a method to redistribute these deaths to specific underlying causes, including suicide [6]. Although GBD 2010 also considered the effects of attempted suicide as ‘non-fatal self-harm’ [5], this was not investigated in this paper.

Literature search to identify relative-risk estimates

We used data sources from recent and methodologically comparable systematic reviews of the association between suicide and mental and substance use disorders [20,24–27], specifically affective disorders, anxiety disorders, schizophrenia (14 studies from these 3 disorder groups) [20], cocaine, opioid, and

amphetamine dependence (24 studies) [24–26] and alcohol dependence (12 studies) [27]. We expanded the Li and collaborators systematic review and replicated the literature search [20] to collect data for bipolar disorder and MDD separately (rather than affective disorders combined), and anorexia nervosa which was not included in the original review. The search strategy used was in keeping with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement [28] (See Text S1 in File S1 for the PRISMA checklist and flow diagram). Electronic databases (Medline and Embase) were searched between 1966 and 2010. A secondary search of reference lists and the grey literature was also conducted. Studies were included that; (1) considered mental and substance use disorders as a risk factor associated with suicide; (2) reported a RR with 95% uncertainty, or provided sufficient information for these to be calculated; (3) were individual-level case-control or cohort studies where a clear temporal association between exposure and outcome could be determined; (4) had a minimum follow up period of 1 year and; (5) included disorders based on ICD [13] or DSM [23] nomenclature to ensure consistency in case definitions. Sex-specific data were preferred but non sex-specific estimates were included (e.g. for substance use disorders) where data were sparse. For each study, information on study methodology, quality and findings were extracted into a Microsoft Excel spreadsheet. See Table S1 in File S1 for a summary of the study variables extracted.

Meta-analysis of relative-risk estimates

For each disorder (except alcohol dependence for which a pooled estimate was available [27]), MetaXL software, an add-in for Microsoft Excel [29], was used to pool RR estimates from different studies. This was done for males and females separately and also combined. RR estimates were pooled using a random effects model, and if there was sufficient data to do so, a quality effects model [30]. Pooled RRs from the quality-effects model were preferred as these gave greater weight to studies of high quality versus studies of lesser quality, and avoided the anomaly of random effects models which revert to equal weighting regardless of sample size if heterogeneity is large [30–32]. Study quality was assessed using a quality index which scored studies based on sampling design and representativeness and also the availability of age- and gender-specific estimates. It was limited to these items to reduce potential subjectivity within and between quality scores. To prevent inter-rater bias, all studies were rated by one researcher and a random sample of scores was checked by an independent researcher. See Table S1 in File S1 for the quality index and scores.

Prevalence of mental and substance use disorders

We obtained the prevalence distribution of each mental and substance use disorder from the epidemiological disease models used in the calculation of direct burden (i.e. YLDs) in GBD 2010 [10,12]. These were based on a separate literature review (presented in greater detail elsewhere [33–38]) conducted between 1980 to 2010 to capture studies reporting prevalence, incidence, remission, duration and all cause-excess mortality associated with mental and substance use disorders. Point (current or past month) prevalence estimates of DSM/ICD defined disorders were required. Twelve-month prevalence estimates were accepted to maximize inclusion but adjusted towards the level of point prevalence using study-level covariates. Lifetime prevalence was excluded as it is more likely than point or period prevalence to be affected by recall bias [39,40]. GBD 2010's DisMod-MR, a Bayesian meta-regression tool, was used to integrate these estimates into an epidemiological disease model. From the

epidemiological inputs, DisMod-MR generated prevalence by sex and age for 187 countries, 21 world regions and 1990, 2005 and 2010 [2,41]. Prevalent cases for each disorder have been summarised in previous publications [2,10,12].

Population attributable fractions

PAFs were calculated from the DisMod-MR prevalence output (P) for each disorder and the pooled RR of suicide given exposure to the disorder. PAFs were calculated by age, sex, country, year and disorder (consistent with the format of GBD 2010 estimates) using the following formula [42]:

$$PAF = \frac{p(RR-1)}{p(RR-1)+1}$$

Given the presence of comorbidity between mental and substance use disorders, disorder-specific PAFs cannot be summed to obtain the 'joint effect' of combined mental and substance use disorders on suicide. Instead, a joint PAF was estimated using the multiplicative method of adjusting for comorbidity between disorders [43]. This can be understood as calculating the complement of the product of the complements of each individual PAF. The following formula was used where i is the individual risk factor, and n is the total number of risk factors [7];

$$Joint\ PAF = 1 - \prod_{i=1}^n (1 - PAF_i)$$

Ceiling values for joint population attributable fractions

Although studies from high income countries have consistently shown that up to 90% of suicides occur as a result of an underlying mental or substance use disorder [18,21,44], there is also evidence to suggest that this proportion is substantially lower in China, Taiwan and India; where symptoms of 'dysphoric affect' and 'impulsivity' (which do not constitute a mental and substance use disorder) are expressed through more lethal methods of self-harming such as pesticide poisoning and self-immolation [45–48]. This in turn, increases the number of completed suicides occurring from self-harm behaviours (characteristically instigated as impulsive acts, without the presence of a mental and substance use disorder or a clear intent to die) in these countries which would have resulted in an "attempted suicide" had such methods not been available [46,47].

So as not to overestimate the total proportion of suicide burden attributable to mental and substance use disorders, we first portioned out global differences in suicide attributable to mental and substance use disorders from differences attributable to other causes. More specifically, the total proportion of suicide cases attributable to mental and substance use disorders in different countries was calculated and used to set a ceiling value (or upper threshold) for the joint PAFs. We examined reference lists of existing reviews for psychological autopsy studies [18,21,44] and conducted a supplementary literature search to capture additional data sources up to 2010. The psychological autopsy method is a retrospective assessment of causes of death which involves canvassing the views of individuals closest to the deceased and substantiating evidence from sources such as hospital and police records [49]. The overall number of suicide cases attributable to mental and substance use disorders was extracted from these studies if DSM/ICD diagnostic criteria [13,23] were used and the number of attributable suicide cases was reported for mental and

substance use disorders as a group rather than for individual disorders. If gender was not recorded we also accepted combined estimates for males and females. Given that there were insufficient data to calculate ceiling values individually for each country or region, we pooled estimates into 2 broad categories based on the percentage of suicide cases reported to be due to mental and substance use disorders. Meta-analyses based on quality effects models were used to generate separate pooled proportions for Group 1: China, India and Taiwan and Group 2: all other countries.

These calculated proportions of suicide cases due to mental and substance use disorder were used to set the ceiling value of joint PAFs. All quantities of interest in GBD 2010 were calculated a thousand times in order to incorporate all sources of uncertainty. Similarly, we created a thousand draws of the ‘ceiling values’ based on the pooled estimates of mean and standard error. When estimating the joint PAFs of suicide attributed to all mental and substance use disorders we did not allow PAF estimates in any of the one thousand draws to exceed the ceiling value in the corresponding draw. For draws that did exceed the ceiling, we scaled down each of the component mental and substance use disorder PAFs by the ratio of the ceiling to the combined PAF.

Attributable burden

The final step was to multiply PAFs by the corresponding GBD 2010 YLLs for suicide [5,6] to calculate attributable burden. Since only completed suicides were considered in our analyses, only YLLs were included in attributable DALY estimates. To quantify 95% uncertainty around our final burden estimate we calculated attributable YLLs and DALYs at the one thousand draw level and bounded the 95% uncertainty interval by the 2.5 and 97.5 centile values. All reporting of DALYs by region and country is based on age-standardised estimates using direct standardization to the global standard population proposed by the World Health Organization (WHO) in 2001 [50].

Results

Pooled relative-risk estimates

Our search culminated in a dataset of 40 studies and 85 RR estimates covering 14 countries (Table S1 in File S1 summarizes included studies). There was a statistically significant increased risk of suicide for all selected mental and substance use disorders (table 1). The greatest risk was seen in MDD followed by schizophrenia, and alcohol dependence. The 95% confidence intervals around each pooled RR indicated high levels of uncertainty with statistical heterogeneity (as measured by the I^2 statistic) of up to 90%. A statistically significant sex difference was only observed for alcohol dependence (Table S2 in File S1 summarizes sex-specific pooled RRs) hence the overall pooled proportions for both sexes combined were used in PAF calculations. Given that the one RR estimate for amphetamine dependence was not statistically different (i.e. occurred within overlapping 95% uncertainty) to the three estimates for cocaine dependence, we combined them to calculate a pooled RR for all psychostimulants. This was used to calculate PAFs for both disorders.

Ceiling values for joint PAFs

Out of 166 psychological autopsy studies reviewed, 43 studies and 57 estimates covering 20 countries were used to calculate ceiling value for joint PAFs (Table S3 in File S1 summarizes included studies). In China, India and Taiwan (group 1), 68.3% (55.2%–80.0%) of suicide cases was due to mental and substance

use disorders which was lower than in all other countries (group 2), where 84.5% (78.6%–89.6%) of suicide cases were due to mental and substance use disorders. These two pooled proportions were used as the ceiling values for joint PAFs from China, India and Taiwan (Group 1) and all other countries (Group 2) respectively. Note that there was considerable heterogeneity between studies. As we found no statistically significant sex difference, the overall pooled proportions were used in PAF calculations (Table S4 in File S1 summarizes sex-specific pooled proportions).

Attributable burden

Mental and substance use disorders were responsible for 22.5 million (14.8–29.8 million) of the 36.2 million (26.5–44.3 million) DALYs allocated to suicide in 2010, amounting to 62.1% (43.8%–75.3%) of total suicide DALYs. The proportion of attributable suicide DALYs in 1990 was almost identical to that in 2010 (62.1% (44.5%–75.4%)). The remainder of this section focuses on 2010 estimates with 1990 estimates summarised in Table S5 in File S1.

There were twice as many mental and substance use disorders attributable suicide DALYs for males (14.9 million (9.5–20.1 million)) compared to females (7.6 million (4.4–10.6 million)). For all disorders, this sex difference was consistent throughout the lifespan. Attributable suicide DALYs were apparent from those aged ≥ 5 years, with the highest proportion occurring between those aged 20–30 years (Figure 1).

The proportion of suicide DALYs explained by mental and substance use disorders was reasonably consistent between regions and within the range of the ceiling values presented in the previous section. When considered in terms of absolute DALYs, Asia South and Asia East had the highest burden attributable to mental and substance use disorders, given their large population size. In terms of age-standardized rates, Europe Eastern had the highest burden (almost 3 times higher than the global mean) and Sub-Saharan Africa West the lowest (6 times lower than the global mean) (Figure 2 and Table S5 in File S1 summarize attributable DALYs by disorder, region, age and sex).

There were also differences in attributable suicide DALYs across countries (plot 1, figure 3). Attributable DALY rates were highest in Kazakhstan and lowest in Saudi Arabia, however many of the country level differences presented in plot 1 were within overlapping ranges of uncertainty (plot 2, figure 3). Except for Guyana, Suriname and Zimbabwe, all countries with statistically higher attributable DALY rates than the global mean were from Eastern Europe and South Asia. Countries with statistically lower DALY rates than the global mean included those from South America, Oceania, Africa and the Middle East and parts of Asia.

Of the suicide DALYs attributable to mental and substance use disorders, MDD was responsible for the largest proportion (46.1% (28.0%–60.8%)), followed by alcohol dependence (13.25% (12.0%–15.0%)), anxiety disorder (7.4% (3.0%–12.7%)), bipolar disorder (5.4% (1.8%–10.7%)), schizophrenia (4.7% (4.1%–5.3%)), amphetamine dependence (2.4% (0.9%–4.6%)), opioid dependence (1.9% (1.1%–2.9%)), cocaine dependence (0.9% (0.3%–1.8%)) and anorexia nervosa (0.2% (0.02%–0.5%)) (figure 4). MDD explained the most suicide DALYs and anorexia nervosa the least across all age groups, sex and regions although most of the age and regional differences between disorders remained within wide and overlapping confidence intervals (Table S6 in File S1).

The additional burden attributable to suicide for each mental and substance use disorder (over and above the DALYs assigned to them as a direct cause) is also illustrated in figure 4. The inclusion of attributable suicide burden increased the fatal burden (YLLs)

Table 1. Pooled relative-risk of suicide in those diagnosed with a mental or substance use disorder.

Disorder	Number of studies	Pooled relative risk (95% UI)
Major depressive disorder	4	19.9 (9.5–41.7)
Anxiety disorder	7	2.7 (1.7–4.3)
Schizophrenia	4	12.6 (11.0–14.5)
Bipolar disorder	4	5.7 (2.6–12.4)
Anorexia nervosa	9	7.6 (2.2–25.6)
Alcohol dependence ^b	12	9.8 (9.0–10.7)
Opioid dependence	21	6.9 (4.5–10.5)
Psychostimulant dependence	4	8.2 (3.9–16.9)
Amphetamine dependence ^a	1	4.5(1.1–9.03)
Cocaine dependence ^a	3	16.9(6.01–47.2)

Note. 95% UI: 95% uncertainty interval;

^aDue to lack of data, simultaneously pooled cocaine and amphetamine relative-risk estimates into an overall estimate for psychostimulants which was applied to both disorders;

^bUsed reported pooled standardised mortality ratios from Wilcox et al [27] for alcohol dependence.

doi:10.1371/journal.pone.0091936.t001

due to mental and substance use disorders from 0.5% (0.4%–0.7%) (assigned to them as a direct cause) to 1.8% (1.4%–2.2%) of global YLLs and the overall burden (DALYs) of mental and substance use disorders from 7.4% (6.2%–8.6%) to 8.3% (7.1%–9.6%) of global DALYs. Out of the 10 leading classes of diseases included in GBD 2010 [5], mental and substance use disorders increased from the 5th to the 3rd leading class of disease burden once the burden attributable to suicide was considered; exceeding the burden due to neoplasms (7.6% (7.0%–8.2%)) of global DALYs and neonatal conditions (8.1% (7.3%–9.0%)) of global DALYs but not cardiovascular and circulatory diseases (11.9% (11.1%–12.7%)) of global DALYs and diarrhea, LRI, meningitis, and other common infectious diseases (11.4% (10.4%–12.8%)) of global DALYs). The global DALY ranking of individual disorders (as presented in GBD 2010's publication series [5]) also increased when attributable suicide burden was included (table 2). Although within overlapping ranges of uncertainty, the ranking for alcohol dependence increased the most, from the 35th (29th–45th) to the 28th (26th–37th) leading cause of burden.

Discussion

Mental and substance use disorders are associated with an increased risk of suicide, a finding that is well established in the literature [19,20,27] but until now, not quantified in terms of a global comparison of disease burden. DALY rankings in GBD 2010 were based on a classification of mutually exclusive disease and injury categories [5,10]. Considering the additional burden due to mental and substance use disorders as a risk factor for suicide elevated mental and substance use disorders from the fifth to the third leading disease category of global burden in 2010. Few mental and substance use disorders are recognized as a primary cause of death in mortality registrations, and those that are recognised are often under-represented. The data presented here provide a more comprehensive insight into the magnitude of the burden due to these disorders.


Mental and substance use disorders were the cause of two-thirds of all suicide DALYs reported in GBD 2010. Aside from emphasising these as a debilitating group of disorders, our findings highlight the importance of prioritising the prevention, early detection and effective management of mental and substance use disorders – particularly MDD – as a key suicide prevention

strategy. Presenting the differences in attributable burden between regions and countries also provides a beginning for developing policies or intervention strategies that are applicable at the national level. Such interventions can be described as 'selective', in the sense that they target subgroups of the population whose members have yet to manifest suicidal behaviours, but exhibit risk factors (in this case, mental and substance use disorders) that predispose them to do so in the future. These can be contrasted with 'universal' interventions, which target whole populations with the aim of favorably shifting proximal and distal risk (and protective) factors across the entire population, and 'indicated interventions' which are designed for individuals already exhibiting suicidal behaviours [51].

Typically, countries that have put in place national suicide prevention strategies have funded a range of universal, selective and indicated interventions, in recognition of the variety of risk and protective factors associated with suicide [52]. However our findings suggest that a relatively greater emphasis on selective interventions targeting individuals with mental and substance use disorders may be applicable. By way of example, equipping general practitioners to detect, diagnose and manage MDD is likely to have benefits, particularly because many individuals with MDD will receive care from a general practitioner rather than a specialist mental health provider. This was one of the few interventions for which there was good evidence of effectiveness as a suicide prevention strategy in a recent review by Mann and colleagues [53]. That said, ensuring that care from general practitioners is evidence-based requires further consideration, given findings that rates of minimally adequate treatment for depression are lower among patients treated solely by general practitioners or in the general medical care sector, compared to those treated by specialist mental health providers [54,55].


However universal and indicated interventions have their place, particularly in low and middle income countries where mental and substance use disorders were associated with a lesser proportion of the burden of suicide. In these countries, universal interventions for example restricting access to means (e.g., pesticides) is worth pursuing given that they are relatively cheap to implement, can have a broad community reach and are known to be effective [53].

Although within overlapping bounds of uncertainty, we found that attributable suicide DALY rates among young people aged 15–19 years were approaching those of the adult age groups.



Note. DALYs: Disability adjusted life years. Plot 1 shows attributable DALYs as proportion of suicide DALYs. Plot 2 shows attributable DALYs as a rate per 100,000


Figure 1. Suicide DALYs attributable to mental and substance use disorders by age and sex, in 2010.
doi:10.1371/journal.pone.0091936.g001




Note. DALYs: Disability adjusted life years; Plot 1 shows attributable DALYs as proportion of suicide DALYs. Plot 2 shows attributable DALYs as a rate per 100,000; AP-HI: Asia Pacific, High Income, As-C: Asia Central, AS-E: Asia East, AS-S: Asia South, A-SE: Asia Southeast, Aus: Australasia, Caribb: Caribbean, Eur-C: Europe Central, Eur-E: Europe Eastern, Eur-W: Europe Western, LA-An: Latin America, Andean, LA-C: Latin America, Central, LA-Sth: Latin America, Southern, LA-Trop: Latin America, Tropical, Nafr-ME: North Africa/Middle East, Nam-HI: North America, High Income, Oc: Oceania, SSA-C: Sub-Saharan Africa, Central, SSA-E: Sub-Saharan Africa, East, SSA-S: Sub-Saharan Africa Southern, SSA-W: Sub-Saharan Africa, West.

Figure 2. Suicide DALYs attributable to mental and substance use disorders by region, in 2010.
doi:10.1371/journal.pone.0091936.g002

Plot 1: Map showing age standardized DALY rates (per 100,000) by country




Plot 2: Map comparing country-specific DALY age standardized rates (per 100,000) to the global mean



Note: DALY: Disability adjusted life years; Low: countries with statistically lower DALY rates than the global mean; middle: countries with statistically similar DALY rates to the global mean; high: countries with statistically higher DALY rates than the global mean.

Figure 3. Suicide DALYs (rates per 100,000) attributable to mental and substance use disorders by country, in 2010. doi:10.1371/journal.pone.0091936.g003



Note. DALYs: Disability adjusted life years; Absolute DALYs in 100,000.

Figure 4. Suicide DALYs attributable to mental and substance use disorders by disorder, in 2010.
doi:10.1371/journal.pone.0091936.g004

Although males had higher rates of attributable burden in most age groups, female rates were higher between the ages of 10 and 19 years. These age-related findings support the importance of school-based prevention programs which include a focus on mental health targeted to at-risk adolescents. The sex-difference in attributable burden also needs to be considered when formulating prevention strategies for this age group. Although evidence of a reduction in suicide behaviours has not been demonstrated, there is evidence for the effectiveness of school-based programs in

reducing the effect of risk factors such as depression [52,56]. A recent systematic review of interventions targeting adolescents or young adults at risk of suicide identified individual cognitive behavioral therapy-based interventions and attachment-based family therapy as promising interventions, requiring further investigation [57].

As there was insufficient data to (1) obtain pooled RR estimates for all countries or regions included in GBD 2010 and (2) clearly detect differences in RR estimates between all countries/regions,

Table 2. Global DALY proportions and rankings before and after the addition of attributable suicide burden, in 2010.

Disorder	After addition of attributable suicide burden (95% UI)			
	Direct DALYs	Mean rank	Direct plus attributable DALYs	Mean rank
	As a proportion of total DALYs		As a proportion of total DALYs	
Major depressive disorder ^a	2.5% (1.9%–3.3%)	11 (7–14)	3.2% (2.5%–4.0%)	8 (4–11)
Anxiety disorder ^a	1.1% (0.8%–1.5%)	26 (19–33)	1.2% (0.9%–1.6%)	25 (17–30)
Alcohol dependence ^a	0.7% (0.5%–0.9%)	35 (29–45)	0.9% (0.7%–1.1%)	28 (26–37)
Schizophrenia ^a	0.6% (0.4%–0.7%)	43 (36–57)	0.7% (0.5%–0.9%)	39 (30.5–50)
Bipolar disorder ^a	0.5% (0.3%–0.8%)	46 (35–59)	0.6% (0.4%–0.8%)	44 (31–56)
Mental and substance use disorders combined ^b	7.4% (6.2%–8.6%)	5 (3–6)	8.3% (7.1%–9.6%)	3 (3–6)

Note. DALYs: Disability adjusted life years; 95% UI: 95% uncertainty interval;

^aGlobal ranking of direct burden for each disorder was from the official GBD 2010 disease ranking for 2010 [5]. Illicit drug use disorders have not been included here as the GBD 2010 official disease ranking investigated drug use disorders as group (rather than by specific drug types). Similarly, the ranking for anorexia nervosa was presented in addition to bulimia nervosa;

^bThe global ranking of direct burden of mental and substance use disorders as a group compares the direct burden of the 11 main classes of diseases in GBD 2010 [10].
doi:10.1371/journal.pone.0091936.t002

the pooled RR estimates used to estimate PAFs were assumed to be constant across age, sex and country. Instead, the variation in attributable DALYs across countries was driven by (a function of both) the prevalence of mental and substance use disorders and the amount of burden accounted for by suicide in each country. In addition, given evidence for differences in the underlying causes of suicide in China, India and Taiwan [45–48], where it has been well documented that the ease of availability of particularly lethal means of self-harm such as pesticides may influence patterns of suicide, we constrained the maximum proportion of suicide attributable to mental and substance use disorders to a ceiling value of 68.3%. In spite of this, some Asian countries were amongst those with the highest rates of attributable suicide burden due to the high rates of suicide in those countries. This emphasizes the fact that although there may be other risk factors for suicide, the prioritisation of mental and substance use disorders in the prevention of suicide remains a global priority.

The maximum proportion of suicide attributable to mental and substance use disorders in all other countries was constrained to a ceiling value of 84.5%. The studies categorized as “all other countries” were mainly from North America, Western Europe and Australia and, although we had data for three low to middle income countries (Colombia, Pakistan and Indonesia), this pooled proportion might not be appropriate for use in Sub-Saharan Africa where we found no data. It is possible that these countries have a different distribution of suicides attributable to mental and substance use disorders but more cross-national RR data are required before we can incorporate this in our findings. Islamic countries, for instance from North Africa/Middle East, were amongst the countries with the lowest proportion of attributable burden, despite being allocated the higher ceiling value of 84.5%. In contrast to the high rates of depression in the Middle East, rates of suicide were low. The lowest rate of suicide recorded in GBD 2010 was from Saudi Arabia. Stigma around suicide due to religious beliefs and legislative prohibition (i.e. suicide being considered as a criminal offence) can lead to fewer cases of suicide being recorded as a cause of death in countries from the Middle East. For similar reasons, the degree of psychopathology underpinning suicide cannot be as clearly assessed in these countries [58,59]. These issues may have biased our estimates of attributable burden. The large bounds of uncertainty presented reflect this to some extent; however, more data are required on the distribution and aetiology of suicide in these countries to improve estimates.

Like all population-based analyses, a number of methodological limitations need to be considered here. The ceiling values for suicide attributable to mental and substance use disorders were derived from psychological autopsy studies. As these collect retrospective data after the individual had died, they are limited by the accuracy of coroners’ reports and systematic bias from interviewees [49]. Although the pooled RR estimates used were derived from more representative population-based prospective cohort studies, there were only a few estimates available for most disorders. We applied the same pooled RR across all countries, sex and age groups for each disorder to reduce errors in estimates as a result of paucity in the data. It is possible that this masked differences in the distribution of attributable suicide DALYs. More representative population cohort studies are now emerging from low and middle income countries such as India [16]. We hope that

the scrutiny of data presented here will encourage more and better quality data collection for mental and substance use disorders as risk factors for suicide. Until then, it is important to consider the uncertainty around our final estimates in interpreting these findings.

CRA methodology assumes a causal relationship between the exposure and outcome [7]. In support for this, the RR estimates used here showed that mental and substance use disorders were significantly associated with suicide risk, even when other risk factors such as socio-economic factors (e.g. adverse marital, employment and socio-economic status) were considered [20,21]. Another assumption was that the proportion of suicide burden attributable to mental and substance use disorders was estimated while holding all other independent risk factors constant. We estimated the joint effect of all mental and substance use disorders on suicide while adjusting for comorbidity between these disorders, the next step would be to explore the joint effect of mental and substance use disorder with other risk factors of suicide. Finally, PAF calculations were sensitive to the exposure distribution used. Here we used DisMod-MR to pool the prevalence of each disorder based on the raw epidemiological data that were available [10,38]. Although this provided consistent prevalence estimates by country, region, age, sex, and year, in some cases DisMod-MR was required to adjust for considerable heterogeneity in the raw data. This was, to some extent, incorporated in our analyses through the 95% uncertainty intervals around all prevalence estimates propagated to the final attributable burden estimates.

Conclusions

Mental and substance use disorders were responsible for two thirds of the suicide burden in 2010, adding a further 22 million DALYs to their global burden. More consideration needs to be given to interventions targeted to populations with, or at risk for, mental and substance use disorders as an effective strategy for suicide prevention.

Supporting Information

File S1 This file contains Text S1 and Tables S1 to S6. (ZIP)

Acknowledgments

We would like to acknowledge members of the mental and illicit drug use expert group and other international collaborators for their assistance with the methodology used in this paper. We would like to specifically thank Abraham D. Flaxman, Institute of Health Metrics and Evaluation, University of Washington, for his assistance with the DisMod-MR modeling of mental and substance use disorders and suicide and Chiara Stone, National Drug and Alcohol Research Centre, University of New South Wales for her assistance with the literature review for illicit drug use disorders.

Author Contributions

Conceived and designed the experiments: AJF TV HAW. Analyzed the data: AJF REN GF EC TV. Wrote the paper: AJF REN GF AJB JEP MGH AP EC LD TV HAW. Wrote the first draft of the manuscript: AJF. Contributed to consequent drafts: REN GF AJB JEP MGH AP EC LD TV HAW.

References

1. Wang H, Dwyer-Lindgren L, Lofgren KT, Rajaratnam JK, Marcus JR, et al. (2012) Age-specific and sex-specific mortality in 187 countries, 1970–2010: a

systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 380: 2071–2094.

2. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, et al. (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 380: 2163–2196.
3. Salomon JA, Wang H, Freeman MK, Vos T, Flaxman AD, et al. (2012) Healthy life expectancy for 187 countries, 1990–2010: a systematic analysis for the Global Burden Disease Study 2010. *Lancet* 380: 2144–2162.
4. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, et al. (2012) Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease 2010. *Lancet* 380: 2129–2143.
5. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, et al. (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 380: 2197–2223.
6. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, et al. (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 380: 2095–2128.
7. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, et al. (2012) A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 380: 2224–2260.
8. Murray CJL, Lopez AD, editors (1996) *The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020*. Cambridge, MA: Published by the Harvard School of Public Health on behalf of the World Health Organization and the World Bank ; Distributed by Harvard University Press.
9. World Health Organization (2008) *The Global Burden of Disease: 2004 update*. Switzerland.
10. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, et al. (2013) The Global Burden of Mental and Substance Use Disorders, 2010. *The Lancet* Published online August 28. Available: <http://www.sciencedirect.com/science/article/pii/S0140673613616116>.
11. Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Murray CJL, et al. (2013) Burden of depressive disorders by country, sex, age and year: Findings from the Global Burden of Disease Study 2010. *PLoS Medicine* In press.
12. Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, et al. (2013) The global burden of disease attributable to illicit drug use: Results from the GBD 2010 study. *The Lancet* Published online August 28. Available: [http://dx.doi.org/10.1016/S0140-6736\(13\)61530-5](http://dx.doi.org/10.1016/S0140-6736(13)61530-5).
13. World Health Organization (1992) *The ICD-10 Classification of Mental and Behavioural Disorders. Clinical descriptions and diagnostic guidelines*. Geneva: World Health Organisation.
14. Prince M, Patel V, Saxena S, Maj M, Maselko J, et al. (2007) No health without mental health. *Lancet* 370: 859–877.
15. Phillips MR, Cheng HG (2012) The changing global face of suicide. *Lancet* 379: 2318–2319.
16. Patel V, Ramasundarathette C, Vijayakumar L, Thakur JS, Gajalakshmi V, et al. (2012) Suicide mortality in India: a nationally representative survey. *Lancet* 379: 2343–2351.
17. Vijayakumar L (2005) Suicide and mental disorders in Asia. *International Review of Psychiatry* 17: 109–114.
18. Arsenaault-Lapierre G, Kim C, Turecki G (2004) Psychiatric diagnoses in 3275 suicides: a meta-analysis. *BMC Psychiatry* 37: 1–11.
19. Harris EC, Barraclough B (1997) Suicide as an outcome for mental disorders: A meta-analysis. *British Journal of Psychiatry* 170: 205–228.
20. Li Z, Page A, Martin G, Taylor R (2011) Attributable risk of psychiatric and socio-economic factors for suicide from individual-level, population-based studies: a systematic review. *Soc Sci Med* 72: 608–616.
21. Yoshimasu K, Kiyohara C, Miyashita K (2008) Suicidal risk factors and completed suicide: meta-analyses based on psychological autopsy studies. *Environmental Health and Preventive Medicine* 13: 243–256.
22. Baxter AJ, Charlson FJ, Somerville AJ, Whiteford HA (2011) Mental disorders as risk factors: assessing the evidence for the global burden of disease study. *BMC Medicine* 9: 1–7.
23. American Psychiatric Association (2000) *Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)*. Washington DC: American Psychiatric Association.
24. Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, et al. (2011) Mortality among problematic users of heroin and other illicit opioids: A systematic review and meta-analysis. *Addiction* 106: 32–51.
25. Degenhardt L, Singleton J, Calabria B, McLaren J, Kerr T, et al. (2011) Mortality among cocaine users: A systematic review of cohort studies. *Drug and Alcohol Dependence* 113: 88–95.
26. Singleton J, Degenhardt L, Hall W, Zabransky T (2009) Mortality among people who use amphetamines: A systematic review of cohort studies. *Drug & Alcohol Dependence* 105: 1–8.
27. Wilcox HC, Conner KR, Caine ED (2004) Association of alcohol and drug use disorders and completed suicide: an empirical review of cohort studies. *Drug Alcohol Depend* 76 Suppl: S11–19.
28. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. *PLoS Med* 6: e1000097.
29. Epigear (2012) MetaXL.
30. Doi SA, Thalib L (2008) A quality-effects model for meta-analysis. *Epidemiology* 19: 94–100.
31. Barendregt JJ, Doi SA (2010) *MetaXL User Guide: Version 1.0*. Wilston, Australia: EpiGear International Pty Ltd.
32. Doi SA, Barendregt JJ, Mozerkewich EL (2011) Meta-analysis Of heterogenous clinical trials: An empirical example. *Contemporary Clinical Trials* 32: 288–298.
33. Baxter AJ, Scott K, Vos T, Whiteford HA (2012) Global prevalence of anxiety disorders: A systematic review and meta-regression. *Psychological Medicine* 43: 897–910.
34. Degenhardt L, Bucello C, Calabria B, Nelson P, Roberts A, et al. (2011) What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. *Drug Alcohol Depend* 117: 85–101.
35. Ferrari AJ, Baxter AJ, Whiteford HA (2010) A systematic review of the global distribution and availability of prevalence data for bipolar disorder. *Journal of Affective Disorders* 34: 1–13.
36. Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, et al. (2013) Global variation in the prevalence and incidence of major depressive disorder: A systematic review of the epidemiological literature. *Psychological Medicine* 43: 471–481.
37. Saha S, Chant D, Welham J, McGrath J (2005) A systematic review of the prevalence of schizophrenia. *PLoS Medicine* 2: e141.
38. Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Degenhardt L (2013) How did we arrive at burden of disease estimates for mental and illicit drug use disorders in the Global Burden of Disease Study 2010? *Current Opinion in Psychiatry* 26: 376–383.
39. Krujshaar ME, Barendregt J, Vos T, de Graaf R, Spijker J, et al. (2005) Lifetime prevalence estimates of major depression: An indirect estimation method and a quantification of recall bias. *European Journal of Epidemiology* 20: 103–111.
40. Moffitt TE, Caspi A, Taylor AJ, Kokaua J, Milne BJ, et al. (2010) How common are common mental disorders? Evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment. *Psychological Medicine* 40: 899–909.
41. Flaxman AD, Vos T, Murray CJL, editors (2013) *An integrative meta-regression framework for descriptive epidemiology*. Washington: University of Washington Press, In press.
42. Bonita R, Beaglehole R, Kjellstrom T (2006) *Basic epidemiology*. Geneva World Health Organization.
43. Haagsma JA, van Beeck EF, Polinder S, Toet H, Panneman M, et al. (2011) The effect of comorbidity on health-related quality of life for injury patients in the first year following injury: comparison of three comorbidity adjustment approaches. *Popul Health Metr* 9: 10.
44. Cavanagh JT, Carson AJ, Sharpe M, Lawrie SM (2003) Psychological autopsy studies of suicide: a systematic review. *Psychological Medicine* 33: 395–405.
45. Conner KR, Phillips MR, Meldrum S, Knox KL, Zhang Y, et al. (2005) Low-planned suicides in China. *Psychol Med* 35: 1197–1204.
46. Phillips MR (2010) Rethinking the role of mental illness in suicide. *Am J Psychiatry* 167: 731–733.
47. Yang GH, Phillips MR, Zhou MG, Wang IJ, Zhang YP, et al. (2005) Understanding the unique characteristics of suicide in China: national psychological autopsy study. *Biomed Environ Sci* 18: 379–389.
48. Zhang J, Xiao S, Zhou L (2010) Mental disorders and suicide among young rural Chinese: A case-control psychological autopsy study. *American Journal of Psychiatry* 167: 773–781.
49. Isometsa ET (2001) Psychological autopsy studies – a review. *European Psychiatry* 16: 379–385.
50. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, et al. (2001) Age standardization of rates: A new WHO standard. WHO.
51. Silverman MM, Maris RW (1995) The prevention of suicidal behaviors: an overview. *Suicide Life Threat Behav* 25: 10–21.
52. Scott A, Guo B (2012) For which strategies of suicide prevention is there evidence of effectiveness? Copenhagen: World Health Organization.
53. Mann JJ, Apter A, Bertolote J, Beautrais A, Currier D, et al. (2005) Suicide prevention strategies: a systematic review. *JAMA* 294: 2064–2074.
54. Briffault X, Morvan Y, Rouillon F, Dardennes R, Lamboy B (2010) [Use of services and treatment adequacy of major depressive episodes in France]. *Encephale* 36 Suppl 2: D48–58.
55. Gabilondo A, Rojas-Farreras S, Rodriguez A, Fernandez A, Pinto-Meza A, et al. (2011) Use of primary and specialized mental health care for a major depressive episode in Spain by ESEMeD respondents. *Psychiatr Serv* 62: 152–161.
56. Katz C, Bolton SL, Katz LY, Isaak C, Tilston-Jones T, et al. (2013) A Systematic Review of School-Based Suicide Prevention Programs. *Depress Anxiety*.
57. Robinson J, Hetrick SE, Martin C (2011) Preventing suicide in young people: systematic review. *Aust N Z J Psychiatry* 45: 3–26.
58. Khan MM (2005) Suicide prevention and developing countries. *J R Soc Med* 98: 459–463.
59. Pritchard C, Amanullah S (2007) An analysis of suicide and undetermined deaths in 17 predominantly Islamic countries contrasted with the UK. *Psychol Med* 37: 421–430.